Skip to content
Screener

Geron GERN Price / sales

Price / sales at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.4×+0.4×
Incyte logo
IncyteINCY
3.9×+1.0×
Immunome logo
ImmunomeIMNM
616.2×+563×
Exelixis logo
ExelixisEXEL
5.5×+1.1×
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
2.6×+0.8×
Gilead Sciences logo
Gilead SciencesGILD
5.2×+0.5×

Other financials

Income statement

See full
Revenue$57.5M+17.2%
Operating income-$12.5M-0.3%
Net income-$16.7M-1.9%
EPS (diluted)-$0.020.0%

Balance sheet

See full
Cash & equivalents$64.5M-18.9%
Total debt$134.1M-0.3%
Total equity$218.6M-15.8%
Total assets$519.0M-6.5%

Cash flow

See full
Operating cash flow-$15.8M+42.3%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$1.01B+13.8%
Enterprise value$1.08B+14.5%

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-28.3%-2.3pp
Debt / equity0.6×+0.1×
Current ratio6.9×-1.0×

Where this comes from

Calculated from Geron’s reported figures.

Based on the most recent quarter.

The source filing: Geron’s 10-Q, filed November 7, 2024. Open the filing →

Filed
Nov 7, 2024
Fiscal quarter
Q3 FY2024
Calendar quarter
Q3 2024
Accession
0000950170-24-123282

FAQ

What is Geron's price / sales?
Geron (GERN) reported price / sales of 92.8× in Q3 2024.
How has Geron's price / sales changed year-over-year?
Geron's price / sales decreased by 97.3% year-over-year, from 3,500.1× to 92.8×.
What is the long-term trend for Geron's price / sales?
Over 3 years (2020 to 2023), Geron's price / sales has grown at a 33.7% compound annual growth rate (CAGR), from 2,023.3× to 4,834.9×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.

Ask your AI about Geron's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude